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Abstract
Background: Diabetic nephropathy is the leading cause of end stage renal failure in the western
world. There is substantial epidemiological evidence supporting a genetic predisposition to diabetic
nephropathy, however the exact molecular mechanisms remain unknown. Transforming growth
factor (TGFβ1) is a crucial mediator in the pathogenesis of diabetic nephropathy.
Methods: We investigated the role of five known single nucleotide polymorphisms (SNPs) in the
TGFB1 gene for their association with diabetic nephropathy in an Irish, type 1 diabetic case (n =
272) control (n = 367) collection. The activity of TGFβ1 is facilitated by the action of type 1 and
type 2 receptors, with both receptor genes (TGFBR1 and TGFBR2) shown to be upregulated in
diabetic kidney disease. We therefore screened TGFBR1 and TGFBR2 genes for genomic variants
using WAVE™ (dHPLC) technology and confirmed variants by direct capillary sequencing. Allele
frequencies were determined in forty-eight healthy individuals. Data for all SNPs was assessed for
Hardy Weinberg equilibrium, with genotypes and allele frequencies compared using the χ2 test for
contingency tables. Patterns of linkage disequilibrium were established and common haplotypes
estimated.
Results: Fifteen variants were identified in these genes, seven of which are novel, and putatively
functional SNPs were subsequently genotyped using TaqMan™, Invader™ or Pyrosequencing®
technology. No significant differences (p > 0.1) were found in genotype or allele distributions
between cases and controls for any of the SNPs assessed.
Conclusion: Our results suggest common variants in TGFB1, TGFBR1 and TGFBR2 genes do not
strongly influence genetic susceptibility to diabetic nephropathy in an Irish Caucasian population.
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Background
Diabetic nephropathy is a major clinical complication of
diabetes mellitus. Epidemiological evidence supporting a
genetic contribution to this disease includes ethnicity dif-
ferences [1], familial clustering [2,3] and the fact that only
a subset of individuals with type 1 diabetes develops dia-
betic nephropathy regardless of metabolic control [4]. In
addition, simulation studies have shown that environ-
mental effects are insufficient to account for the familial
aggregation of this disease [3,5].
Transforming growth factor beta (TGFβ1) is a multifunc-
tional cytokine implicated in the pathogenesis of many
forms of progressive renal disease, including diabetic
nephropathy, by promoting renal hypertrophy and the
accumulation of extracellular matrix [6]. Protein and
mRNA levels of TGFβ1 are significantly increased in the
renal glomeruli and tubulointerstitium of animal models
of diabetes and in humans with diabetes [7]. TGFβ1 is
transcriptionally activated by high extracellular glucose in
murine glomerular mesangial cells [8]. Transgenic mice
over-expressing TGFβ1 develop progressive renal failure,
suggesting that chronically elevated levels of circulating
TGFβ1 are integral to the pathogenesis of kidney disease
[9,10]. Direct blockade of TGFβ protein by chronic
administration of anti-TGFβ1 antibodies has been shown
to decrease renal insufficiency [11]. In addition, antisense
TGFβ1 oligonucleotides reduce the cellular hypertrophy
and stimulation of matrix synthesis normally seen in
renal cells exposed to high extracellular glucose [12].
The activity of TGFβ1 in regulating cell proliferation, dif-
ferentiation and extracellular matrix production are medi-
ated by a heterodimeric complex of type 1 and type 2
receptors. Upregulation of TGFβ1 receptors have been
reported in animal models of glomerulosclerosis [13,14].
It has been proposed that upregulation of TGFβR2
induced by high extracellular glucose may contribute to
distal tubular hypertrophy in diabetic nephropathy [15].
Isono and colleagues demonstrated that increased expres-
sion of TGFβR2 in the diabetic kidney is primarily due to
stimulation of gene transcription rather than increased
mRNA stability [16].
TGFβ1 is encoded by the TGFB1 gene located at chromo-
some 19q13.1 [17]. We have investigated the role of five
known single nucleotide polymorphisms, which may
influence  TGFB1  gene expression (TGFB1: -800G>A, -
509C>T, +72InsC, +869T>C, +915G>C) for their associa-
tion with diabetic nephropathy. TGFβ receptors type 1
and type 2 are encoded by TGFBR1 and TGFBR2 genes
respectively. At present there are over six hundred variants
recorded in dbSNP for these genes, with little information
available on the role of these variants in relation to renal
complications of diabetes. We have screened the genomic
draft sequence for the TGFBR1 and TGFBR2 genes in an
Irish population to identify genomic variants. Allele fre-
quencies were subsequently determined in a healthy con-
trol population and selected SNPs genotyped in a case-
control collection. In summary, we investigated if puta-
tively functional variants in three genes, TGFB1, TGFBR1
and TGFBR2, contribute to genetic susceptibility to dia-
betic nephropathy in type 1 diabetes.
Methods
Subjects
Ethical approval was obtained from the appropriate
Research Ethics Committees in each country and written,
informed consent obtained from individuals prior to con-
ducting this study. The case and control groups used for
this study (Table 1) have been described previously [18].
All patients were at least third generation Irish Caucasians
diagnosed with type 1 diabetes mellitus before 31 years of
age, and required insulin from diagnosis. Patients with
nephropathy (cases, n = 272) had diabetes for at least 10
years before the onset of proteinuria (>0.5 g/24 h).
Patients without nephropathy (controls, n = 367) had dia-
betes for at least 15 years, were not in receipt of antihyper-
tensive medication, and had no evidence of non-diabetic
renal disease. Patients with microalbuminuria were
excluded from both groups.
In silico analysis
For TGFBR1, the nucleotide sequence of draft clone RP11-
96L7 for human chromosome 9 was downloaded from
the National Centre for Biotechnology Information [19].
Similarly, the sequence for TGFBR2 was obtained for draft
clone RP11-1024P17 on human chromosome 3. Refer-
ence mRNA (NM_004612; NM_003242) and protein
(NP_004603; NP_003233) sequences were also down-
loaded from NCBI for TGFBR1 and TGFBR2 respectively.
These were used to determine intron-exon boundaries for
genomic DNA using Vector NTI Advance (suite 2, version
8, Informax Inc (Europe), Oxford, UK). The nomenclature
for all identified variants follows the Human Genome
Variation Society recommendations for coding sequences,
updated 21st May 2005 [20]. In addition, we have pro-
vided rs numbers for all previously identified SNPs and ss
numbers for novel SNPs to facilitate ease of comparison
between research groups.
Amplification and mutation screening
6464 bases of TGFBR1  and 5204 bases of TGFBR2
genomic sequences were divided into fragments with an
average size of approximately 500 base pairs, for PCR and
screening purposes in 15 case and 15 control individuals.
As the TGFBR1 and TGFBR2 gene sequences cover approx-
imately 45 kb and 84 kb respectively from start to stop
codon, only the coding regions of these genes (including
all exons, exon-intron boundaries and untranslatedBMC Medical Genetics 2007, 8:5 http://www.biomedcentral.com/1471-2350/8/5
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regions) were screened to prioritise the identification of
potentially functional gene variants. Each PCR product
was then evaluated using WaveMaker v3.4 software
(Transgenomic Ltd, Crewe, UK) and analysed on the
WAVE™ (dHPLC) DNA Fragment Analysis System (Trans-
genomic Ltd) following the manufacturer's recommenda-
tions. Differentially separating fragments (representing
DNA variants) were bidirectionally sequenced to identify
variants using an ABI PRISM®  3100 Genetic Analyser
(Applied Biosystems, Warrington, UK). Forty-eight
healthy controls (n = 96 chromosomes) from the Young
Hearts collection [21] (a healthy Irish Caucasian popula-
tion) were genotyped by direct capillary sequencing
(Applied Biosystems) to establish allele frequencies for all
gene variants.
Genotyping
Five SNPs were selected for genotyping in the TGFB1 gene
as they have been previously suggested to influence the
expression of TGFβ1, in addition to demonstrating a
minor allele frequency greater than 5%. TaqMan assays
were successfully designed for TGFB1:  -800G>A
(rs1800468),  TGFB1:  -509C>T (rs1800469), TGFB1:
+869T>C (rs1982073) and TGFB1:  +915G>C
(rs1800471) SNPs, but proved problematic for TGFB1:
+72InsC (rs1800999) due to the presence of a long C
homopolymer. TGFB1:  +72InsC was successfully geno-
typed using a biplex Invader™ assay (Third WAVE Tech-
nologies Inc, Madison, MI, USA). Genotyping was
performed for receptor variants using Pyrosequencing®
technology according to the manufacturer's instructions
(Biotage, Uppsala, Sweden). Details of the primer
sequences used for resequencing purposes, together with
the WAVE conditions and the oligos used for the genotyp-
ing assays are listed (Tables 2, 3, 4, 5) with further details
readily available from the authors on request. 272 case
and 367 control samples were available for genotyping
TGFB1 SNPs, however fewer samples were available (241
cases and 322 controls) for genotyping TGFBR2 gene var-
iants. Genotype frequencies were assessed for Hardy-
Weinberg equilibrium using a χ2 goodness-of-fit test. The
χ2 test for contingency tables was used to compare geno-
type and allele frequencies between case and control sub-
jects with the level of significance set to p < 0.05.
Haploview [22] was used to visualise linkage disequilib-
rium (LD) and haplotype blocks within each gene.
Results
We have submitted our annotated sequencing data for
TGFBR1 and TGFBR2 genes as GenBank accession num-
bers DQ383416 – DQ383424 and DQ377553 –
DQ377559 respectively. A total of fifteen variants were
identified in these genes (TGFBR1, n = 5; TGFBR2, n = 10)
of which eight were previously recorded in dbSNP; we
have obtained unique NCBI identifiers for all novel SNPs
(n = 7; Table 6).
The distribution of genotypes was found to be in Hardy-
Weinberg equilibrium for all SNPs in both case and con-
trol groups. No significant differences were observed in
genotype and allele frequencies between case and control
groups for any of the SNPs assessed (Table 7). Logistic
regression analysis for the clinical characteristics
described in Table 1 did not reveal a significant associa-
tion with any variant and diabetic nephropathy. Adjusted
p values for these potential covariates are shown in Table
8.
The level of observed LD between all genotyped variants
within each gene, together with the raw |D'| and R2 scores
are shown in the Figures (Figures 1, 2). The most common
combinations of alleles observed 5' to 3' were GC-TG
Table 1: Clinical characteristics of cases (n = 272) and controls (n = 367) (Data are n, mean ± SD)
Criteria Cases Controls
N 272 367
Gender
Male 61.4 % 40.3 %
Female 38.6 % 59.7 %
Age at Diagnosis (years) 17.1 ± 8.2 16.8 ± 8.1
*Duration of Diabetes (years) 26.9 ± 8.3 27.7 ± 9.0
HbA1C (%) 8.5 ± 1.7 8.4 ± 1.6
BMI (kg/m2) 26.0 ± 3.8 26.2 ± 3.5
Systolic Blood Pressure (mm Hg) 150.1 ± 22.6 126.9 ± 16.6
Diastolic Blood Pressure (mm Hg) 86.5 ± 11.4 76.1 ± 7.3
* Duration of diabetes was calculated from the date of diagnosis of diabetes to date of recruitment
* BMI = body mass indexBMC Medical Genetics 2007, 8:5 http://www.biomedcentral.com/1471-2350/8/5
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(49.4%); AC-TG (12.6%) and GT-CG (10.5%). In addi-
tion, we have identified a novel, rare variant at TGFB1:
+728T>C (ss50394786).
Discussion
There is considerable evidence supporting the role of
TGFB1, TGFBR1 and TGFBR2 genes in the development of
diabetic nephropathy. The functional importance of the
TGFβ1 protein is illustrated by the high degree of conser-
vation observed across mammalian species. The TGFβ1
gene comprises seven exons separated by relatively large
introns [23]. Transcriptional regulation is complex with
two major start sites identified at positions +1 and +271
[24]; polymorphic positions are typically reported relative
to the first major transcription start site for this gene. We
have assessed five SNPs, suggested to play a role in TGFβ1
expression levels through their impact on regulatory
regions of TGFB1 [25-27], for association with diabetic
nephropathy. Genotype and allele frequencies were simi-
lar to those reported in other European populations, with
a decreased frequency observed for the minor alleles of
TGFB1: -509C>T and TGFB1: +869T>C compared to the
ECTIM results [25,28,29]. As illustrated by the LD Plots
(Figures 1, 2), we observed low correlation between the
genotyped SNPs. The |D'| values suggest that these SNPs
have been separated by recombination, however as the
magnitude of |D'| is biased for smaller sample sizes |D'|,
lower values may be difficult to interpret. To further clarify
the patterns of LD between genetic markers, we also exam-
ined R2 values as this measure of LD is not as susceptible
to small sample sizes. It is important to note that |D'| is
less than one only when all haplotypes are observed and
that markers with disparate alleles frequencies will also
affect these measures of LD. The patterns of LD indicate
that all genotyped loci within each gene are not contained
within a single haplotype block, thereby suggesting lim-
ited value in performing haplotype analysis – i.e. the LD
values suggest that these markers are not transmitted on a
single haplotype, but are separated by recombination
events. Our analysis suggests that all SNPs genotyped in
this study are informative and the most common combi-
nations of alleles observed are similar to those previously
published [29]. Comparison of our data with Phase II,
release 21 of the HapMap resource [30] supports our find-
ings that the TGFB1 gene is located in a genomic region
affected by a recombination hotspot. All recorded poly-
morphic sites in the HapMap CEPH (Utah residents with
ancestry from northern and western Europe) population
demonstrate poor correlation, suggesting that all should
therefore be genotyped as 'tag' SNPs. None of the com-
mon variants genotyped for the TGFB1 gene in this study
are recorded as polymorphic in the Phase II, release 21
HapMap Caucasian data set and the nearest polymorphic
SNP is approximately 2 kb from our SNPs of interest.
Table 2: Primer sequences used for screening TGFBR1 and TGFBR2 genes
Primer Set Primer 1 Primer 2
TGFBR1 i tcctccttaaaaggttctgc agaaagtcctcagatcccag
TGFBR1 ii ggaggctatttgggggtgt gcgagcgccggtttctg
TGFBR1 iii actcacacagacacaccca aagagcaggagcgagccag
TGFBR1 iv ctaagagcaacaaacagtgc gtcacttcttgcctctaaacg
TGFBR1 v tgcaggaattgtgtaggattg tggagctgacttattgattcg
TGFBR1 vi ctccccagtgagataaattc aatcttgaagaagttcctag
TGFBR1 vii gcttactctgaggaactaaag agatgcggttttgtcatgttg
TGFBR1 viii aagtattgtaggtcatgtgg gatattttctggaagggcaac
TGFBR1 ix gtctgaaaggaggttcatc caggaagagaatacactagg
TGFBR1 x gtgatcttttaatgccttgg aacattggtttgactgcta
TGFBR1 xi caccagtaccctattgatgg aaggagagttcaggcaaagc
TGFBR1 xii gcaactcagtcaacaggaag gaatcaaggaaactctagtgg
TGFBR1 xiii agaaagtgatttactcct g attcaaacatgaccatgc
TGFBR1 xiv ctttctcctaccaaaatgtgc ctgaattaaaagctgccttcc
TGFBR2 i cctcctggctggcgagcg ggaccaaacgtgccccgc
TGFBR2 ii aagcaaatggctactcaacc acacatacatgcagagaacacc
TGFBR2 iii tgcgaatgctggagaacagg ggaggacaccacctaacgtatg
TGFBR2 iv agctgaagtttgaaggaagagc gcacacggttgttgtagttggt
TGFBR2 v catcatcttctactgctaccgc ggttcccgttggatgtcctcat
TGFBR2 vi ggagttggggaaacaatactgg gggtcaagtcgtgtaaaaaagg
TGFBR2 vii ctatctgtacctttctgtgc ccaatacgatttgtcggatc
TGFBR2 viii gttacttagtgcttcatgctcc ccttccagggtaacacaagata
TGFBR2 ix gtgttgggagtgttagtgtacc ccgtaggtctaccacacactct
TGFBR2 x accaactcatggtgccctttgg cggtatggaacttttctctg
TGFBR2 xi gctgtgttagcacttcctcagg ggtttagaccccccgatcaaat
TGFBR2 xii tgtttgaggaccagtgttcccg ccgaggactaacgagttcgtgtBMC Medical Genetics 2007, 8:5 http://www.biomedcentral.com/1471-2350/8/5
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Table 3: WAVE conditions used for screening TGFBR1 and TGFBR2 genes.
Primer Set Tm°C Melt Range°C Run Temperature°C WAVE Buffer B (%)
TGFBR1 i 59.4 54 – 72 57 69–79
59 67–77
64 62–64
TGFBR1 ii 63.3 60 – 72 63 68–78
69 62–72
TGFBR1 iii 69.2 58 – 75 69 68–78
72 65–75
TGFBR1 iv 55.9 54 – 65 55 68–78
59 64–74
TGFBR1 v 57.2 54 – 65 55 62–72
59 58–68
61 56–58
TGFBR1 vi 56.1 54 – 65 56 68–78
59 65–75
TGFBR1 vii 56.5 54 – 68 55 69–79
58 66–76
TGFBR1 viii 57.0 54 – 65 57 67–77
TGFBR1 ix 57.4 55 – 67 56 67–77
58 64–75
62 61–71
TGFBR1 x 54.8 51 – 66 54 65–75
57 62–72
TGFBR1 xi 54.6 54 – 67 54 65–75
58 60–70
TGFBR1 xii 56.9 55 – 65 56 64–77
58 62–72
TGFBR1 xiii 55.8 52 – 62 56 67–77
TGFBR1 xiv 55.2 54 – 63 55 67–77
59 63–73
TGFBR2 i 66.1 59–74 60 63–73
65 58–68
67 56–66
70 53–63
TGFBR2 ii 66.3 61 – 72 64 58–68
66 56–66
69 52–62
TGFBR2 iii 58.5 57 – 61 59 61–71
61 59–69
TGFBR2 iv 59.8 55 – 65 56 67–77
61 60–70
63 58–68
TGFBR2 v 60.5 57–64 62 58–68
TGFBR2 vi 63.5 62–65 64 55–65
TGFBR2 vii 59.7 53–71 59 57–67
61 52–62
TGFBR2 viii 59.7 53 – 71 59 66–76
61 64–74
TGFBR2 ix 61.0 60–61 61 57–67
TGFBR2 x 57.0 51–66 52 63–73
58 57–67
62 53–63
64 50–60
TGFBR2 xi 54.4 53 – 66 54 67–77
56 65–75
60 61–71
TGFBR2 xii 57.0 56–60 59 63–73BMC Medical Genetics 2007, 8:5 http://www.biomedcentral.com/1471-2350/8/5
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We observed no significant differences in genotype or
allele frequencies between case and control groups for any
of the SNPs assessed. The TGFB1: +869T>C SNP has been
associated with diabetic nephropathy in a Chinese popu-
lation with type 2 diabetes [31], however our results do
not support this finding for nephropathy in type 1 diabe-
tes. The results from Wong and colleagues' smaller Chi-
nese study (cases, n = 58; controls, n = 65), may be
explained by a difference in genetic factors between type 1
and type 2 diabetes or differences between the Chinese
and Irish populations.
Our study employed rigorous phenotypic criteria for
inclusion of cases and controls. The annual incidence of
diabetic nephropathy increases over the first fifteen to
twenty years duration of type 1 diabetes, but after twenty-
five years the absence of overt proteinuria makes the sub-
sequent development of nephropathy unlikely [32,33].
The present report utilised cases and controls that were
well matched for prolonged duration of diabetes (cases
mean duration = 26.9 ± SD 8.3 years, control mean dura-
tion = 27.7 ± SD 9.0years). Our results for TGFB1 are in
accord with Ng and colleagues' study which also failed to
find an association between the TGFB1:  -800G>A, -
509C>T, +869T>C or +915G>C polymorphisms and dia-
betic nephropathy in US Caucasians with type 1 diabetes
[34]. This is in contrast to a larger study in UK Caucasians
where a significant association (p = 0.027) was identified
between TGFB1: +869T>C and diabetic nephropathy [35].
This UK study utilised the Golden Years cohort of type 1
diabetic individuals as a control population [31] with all
the recruited subjects (n = 410) having a very long dura-
tion of type 1 diabetes (> 50 years). Although these indi-
viduals did not have renal failure due to diabetic
nephropathy 29% were taking antihypertensive medica-
tion and 35.7% had evidence of micro- or macroalbu-
minuria [36]. These clinical features (antihypertensive
medication and micro- or macroalbuminura) form dis-
tinct exclusion criteria from our own diabetic control
group. Although our sample size has ~90% power to
detect a doubling in the minor allele frequency in cases
relative to controls (e.g. 10% vs. 5%), there is a need for a
collaborative genotyping effort in larger sample collec-
tions to definitively determine the role of these SNPs in
predisposition to diabetic nephropathy.
TGFβ type I receptors form a heterodimeric complex with
TGFβ type II receptors and bind to TGFβ to mediate many
TGFβ activities including regulation of cell proliferation,
differentiation and extracellular matrix production. It has
been recently reported that TGFβ1-mediated epithelial-to-
mesenchymal transition requires functional TGFBR2 [37].
Variants have been recorded for both TGFBR1  and
TGFBR2 genes, however there is limited genomic informa-
tion regarding their influence on diabetic nephropathy.
TGFBR1 is composed of nine exons and maps to chromo-
some 9q33-q34 [38]. TGFBR2 is composed of seven exons
and maps to 3p22 [39]. There are presently 409 validated
SNPs recorded in dbSNP for these two genes (TGFBR1, n
= 115; TGFBR2, n = 294; dbSNP, accessed 12/01/06). Due
to the large number of reported SNPs and potential ethnic
variation in SNP occurrence and frequency [40], we rese-
quenced these genes in our population.
We prioritised screening of the protein coding regions of
these genes to aid identification of potentially functional
gene variants. We screened for variants directly affecting
lariat regions, splice sites, exonic/intronic splice enhanc-
Table 4: TaqMan primers, probes, quencher and annealing temperature for relevant assays.
Primer set Primer 1 Primer 2 FAM™ Labelled 
Probe
Vic™ Labelled Probe Fluorescent 
Quencher
Anneal 
(1 minute)
TGFB1 -800G>A gctatcgcctgcacacagc aggacagaagcggtcccat tgcctccaacgtcaccaccatc tctgcctccaacatcaccaccatc TAMRA 62°C
TGFB1 -509C>T ttagccacatgggaggtgct ccaggcggagaaggcttaa acccttccatccctcaggtgtcct ccctcccatccttcaggtgtcctg TAMRA 62°C
TGFB1 +869T>C caccacaccagccctgttc ccaggcgtcagcaccagta agcagcggcagca cagcagcagcagc None 60°C
TGFB1 
+915G>C
Developed by Applied Biosystems (USA) as a Research and Development Kit None 56°C
TGFBR1+72InsC was genotyped by a commercial Invader kit designed and manufactured by Third WAVE technologies (Madison, MI, USA)
Table 5: Pyrosequencing primers, dispensation order and sequence to analyse for relevant assays
Primer Set Forward Primer Reverse Primer Sequence Primer Dispensation order Sequence to 
Analyse
TGFBR2 c.*747C>G tcctgtgtgcccttatttctc tgaaggtaaaaagtggggttc agtttctaaactaggttgag tcgagagtctac c/ggagagtttctaaac
TGFBR2 c.1149G>A gatcacactccatgtggg ccagacgcagggaaagc agagctccaatatcctc tgatgagacgac tac g/atgaagaacgacctaaccBMC Medical Genetics 2007, 8:5 http://www.biomedcentral.com/1471-2350/8/5
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Table 6: Minor allele frequencies of identified variants in TGFBR1 and TGFBR2 genes, based on genotyping of 48 healthy control 
individuals. Accepted GenBank accession numbers for the reference sequences describing TGFBR1 and TGFBR2 gene variants are 
DQ383416 – DQ383424 and DQ377553 – DQ37759 respectively.
Variant Unique NCBI Identifier Minor Allele Frequency (%)
aTGFBR1: c.694A>C ss50394789 4.3
aTGFBR1: c.*899T>C ss50394790 2.2
aTGFBR1: c.*921T>G ss50394793 4.3
aTGFBR1: c.*978G>A ss50394791 1.1
aTGFBR1: c.*1004A>T ss50394792 2.2
TGFBR2: c.263+7A>G rs1155705 10.8
aTGFBR2: c.263+17A>C ss50394787 1.1
TGFBR2: c.445-111A>G rs17026161 2.2
TGFBR2: c.445-4T>A rs11466512 21.7
aTGFBR2: c.1149G>A ss50394788 1.1
TGFBR2: c.1157C>T rs2228048 2.2
TGFBR2: c.1515-91C>A rs2276767 4.3
TGFBR2: c.*327-329delAT rs4016180 21.7
TGFBR2: c.*747C>G rs11466531 7.6
TGFBR2: c.*835C>A rs17026332 2.2
aNovel SNPs accepted by dbSNP
Table 7: Genotype and allele frequencies of selected SNPs in case and control groups. The five TGFB1 SNPs were selected on the basis 
of previous publications [23-27]. The remaining two TGFBR2 SNPs were selected from potentially functional SNPs identified through 
screening the gene as summarised in Table 1. Data are n (%)
SNP Genotype Case Control p value Allele Case Control p value
TGFB1 -
800G>A
GG 188 (69.1) 268 (73.0) 0.56 G 454 (83.5) 628 (85.6) 0.30
GA 78 (28.7) 92 (25.1)
AA 6 (2.2) 7 (1.9) A 90 (16.5) 106 (14.4)
TGFB1 -
509C>T
CC 179 (65.8) 245 (66.8) 0.62 C 442 (81.3) 595 (81.1) 0.93
CT 84 (30.9) 105 (28.6)
TT 9 (3.3) 17 (4.6) T 102 (18.7) 139 (18.9)
TGFB1 
+72InsC
- C 221 (81.3) 301 (82.0) 0.88 - C 488 (89.7) 663 (90.3) 0.71
+/- C 46 (16.9) 61 (16.6)
+ C 5 (1.8) 5 (1.4) +C 56 (10.3) 71 (9.7)
TGFB1 
+869T>C
TT 151 (55.5) 204 (55.6) 0.86 T 403 (74.1) 540 (73.6) 0.84
TC 101 (37.1) 132 (36.0)
CC 20 (7.4) 31 (8.4) C 141 (25.9) 194 (26.4)
TGFB1 
+915G>C
GG 219 (80.5) 298 (81.2) 0.98 G 488 (89.7) 661 (90.1) 0.84
GC 50 (18.4) 65 (17.7)
CC 3 (1.1) 4 (1.1) C 56 (10.3) 73 (9.9)
aTGFBR2 
c.*747C>G
CC 218 (90.5) 287 (89.1) 0.88 C 457 (94.8) 606 (94.1) 0.61
CG 21 (8.7) 32 (9.9)
GG 2 (0.8) 3 (0.9) G 25 (5.2) 38 (5.9)
aTGFBR2 
c.1149G>A
GG 232 (96.3) 317 (98.4) 0.10 G 473 (98.1) 639 (99.2) 0.10
GA 9 (3.7) 5 (1.6)
AA 0 0 A 9 (1.9) 5 (0.8)
a 272 cases and 367 controls were genotyped for TGFB1 SNPs with 241 cases and 322 controls genotyped for TGFBR2 variants.BMC Medical Genetics 2007, 8:5 http://www.biomedcentral.com/1471-2350/8/5
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ers, signal sequences, protein coding sequence, polyade-
nylation signals and untranslated regions. It is possible
that other variants may affect regulatory mechanisms,
(promoter or enhancer elements, microRNA etc.) or that
features such as post-translation modifications may affect
these candidate genes and their subsequent protein activ-
ity. It is also possible that rare variants may play a role in
susceptibility to diabetic nephropathy; however this study
lacks sufficient sample numbers to definitively assess the
role of rare variants in this disease. Five novel variants
were identified in TGFBR1, of which none were at suffi-
cient frequency to assess in this case-control collection.
We have identified nine SNPs in TGFBR2. Two SNPs are
located in exons (TGFBR2:  c.1157C>T,  TGFBR2:
c.1149G>A) and one SNP in the 3' UTR which was found
to be putatively functional (TGFBR2: c.*747C>G). Analy-
sis of TGFBR2: c.*747C>G genotyping did not reveal a sig-
nificant association with diabetic nephropathy. A
microsatellite [AT]del was also identified in the 3' UTR of
TGFBR2. TGFBR2: c.1157C>T in exon four was found in
only one sample in the heterozygous state (MAF: 1.1%),
and does not lead to a change in amino acid (aac → aat =
N389N). TGFBR2: c.1149G>A was found in only two sam-
ples (MAF: 2.2%), but leads to a non-synonymous change
in amino acid (gtg → atg = V387M) in the serine-threonine
protein kinase active domain of the mature chain for
TGFβR2 (PROSITE: PS00108; Pfam: PF00069, accessed
03/02/06). Genotyping TGFBR2:  c.1149G>A did not
reveal a significant association with diabetic nephropathy,
however we did identify a doubling of the minor allele in
cases (MAF: 1.9% in cases vs. 0.8% in controls). This find-
ing may be due to the low frequency of minor allele, how-
ever our available sample numbers do not provide
sufficient power to appropriately assess the association of
this SNP with diabetic nephropathy. The search for causa-
tive variants for susceptibility to diabetic nephropathy is
constrained by limited numbers of well-characterised,
precisely phenotyped cases and controls, which represents
a major challenge in the study of complex disease genet-
ics. While the power to identify disease gene loci is influ-
enced by many factors, the requirement for adequate
samples sizes of stringently phenotyped individuals is crit-
ical to the success and validity of complex disease associ-
ation studies. Our results warrant further investigations of
rare variants, particularly the TGFBR2 exonic SNPs, pro-
vided the sample population is sufficiently powered to
assess the association.
Conclusion
Although experimental evidence suggests TGFβ1 blockade
may be an important therapeutic target we were unable to
identify any association between TGFB1 gene variants and
diabetic nephropathy. In resequencing the genes we iden-
tified eight novel variants for TGFB1, TGFBR1 and
TGFBR2 genes but did not detect significant association
between any of the common SNPs and nephropathy in
this Caucasian population with type 1 diabetes.
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